首页 > 市场调查报告书 > 製药

自体免疫疾病

市场调查报告书

商品编码

1608740

硬皮症药物市场：依药物类别、类型、给药途径、分销管道、地区

Systemic Scleroderma Treatment Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年11月15日 | 出版商:

Coherent Market Insights | 英文 164 Pages | 商品交期: 2-3个工作天内

价格

简介目录

系统性硬皮症药物市场预计 2024 年价值 17.1 亿美元，预计 2031 年将达到 23.9 亿美元，2024 年至 2031 年复合年增长率为 4.9%。

分析范围		分析详情
基准年	2023年	市场规模（2024年）	17.1亿美元
实际资料	2019-2023	预测期	2024-2031
预测期复合年增长率（2024-2031）	4.90%	预计金额（2031年）	23.9亿美元

图：2024年系统性硬皮症药物市场占有率（%），依地区划分

系统性硬皮症是一种慢性自体免疫结缔组织疾病，会导致皮肤和结缔组织硬化和收紧。其特征是身体细胞和组织中胶原蛋白过度生成，导致纤维化和疤痕。目前，系统性硬皮症尚无确定的治疗方法，可用于控制症状和减缓疾病进展的治疗方法也有限。系统性硬皮症治疗市场包括药物、治疗剂、医疗设备和其他用于治疗疾病的产品。由于患病率上升和治疗选择有限，预计该市场在未来几年将大幅增长。

市场动态：

全球系统性硬皮症治疗市场是由全球系统性硬皮症发病率和盛行率不断增加所推动的。据硬皮症基金会称，美国约有 30 万人，全世界有数百万人患有硬皮症。然而，对该疾病发病机制的了解有限、缺乏治疗选择以及缺乏核准的全身性药物，对市场成长构成了挑战。然而，正在进行的新药和治疗方法研究有可能扩大治疗领域。此外，到 2030 年，主要市场医疗保健成本的上升预计将推动市场扩张。

本报告的主要特点

本报告对全球系统性硬皮症治疗药物市场进行了详细分析，并列出了以2023年为基准年的预测期（2024-2031年）的市场规模和复合年增长率。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球系统性硬皮症治疗市场的主要企业进行了分析。

本报告涵盖的主要企业包括：GSK plc、Certa Therapeutics、Aisa Pharma, Inc.、Corbus Pharmaceuticals、AbbVie, Inc.、Biogen、Novartis AG、AstraZeneca、Celgen Corporation、ONO PHARMACEUTICAL CO., LTD.、Teva Pharmaceutical .、勃林格殷格翰国际有限公司及MediciNova, Inc.

该报告的见解使负责人和公司经营团队能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。

全球系统性硬皮症治疗药物市场报告针对该行业的各个相关人员相关者，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球硬皮症治疗药物市场的各种策略矩阵，将促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	1.71 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	4.90%	2031 Value Projection:	2.39 Bn

Systemic scleroderma is a chronic autoimmune connective tissue disorder that causes hardening and tightening of the skin and connective tissues. It is characterized by the overproduction of collagen in the cells and tissues of the body leading to fibrosis or scarring. Currently, there is no cure for systemic scleroderma and the treatment options are limited to manage its symptoms and slow disease progression. The systemic scleroderma treatment market comprises drugs, therapies, medical devices and other products being used to treat this condition. With rising prevalence and limited treatment options, this market is poised to grow significantly in the coming years.

Market Dynamics:

The global systemic scleroderma treatment market is driven by the increasing incidence and prevalence of systemic scleroderma worldwide. According to Scleroderma Foundation, around 300,000 people in the U.S. and millions worldwide suffer from scleroderma. However, limited understanding of disease etiology, scarce treatment options, and lack of approved drugs for systemic forms pose challenges to market growth. Nonetheless, ongoing research on novel drugs and therapies holds promise to widen the treatment landscape. Furthermore, rising healthcare expenditures in major markets will facilitate market expansion through 2030.

Key Features of the Study:

This report provides in-depth analysis of the global systemic scleroderma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global systemic scleroderma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GSK plc, Certa Therapeutics, Aisa Pharma, Inc., Corbus Pharmaceuticals, AbbVie, Inc., Biogen, Novartis AG, AstraZeneca, Celgen Corporation, ONO PHARMACEUTICAL CO., LTD., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., and MediciNova, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global systemic scleroderma treatment market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- Immunosuppressant
- Phosphodiesterase 5 inhibitors - PHA
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Prostacyclin Analogues
- Others
Type Insights (Revenue, USD Bn, 2019 - 2031)
- Limited Systemic Sclerosis
- Diffused Systemic Sclerosis
- Sine Sclerosis
Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Parenteral
- Others
Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- GSK plc
- Certa Therapeutics
- Aisa Pharma, Inc.
- Corbus Pharmaceuticals
- AbbVie, Inc.
- Biogen
- Novartis AG
- AstraZeneca
- Celgen Corporation
- ONO PHARMACEUTICAL CO., LTD.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH.
- MediciNova, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Systemic Scleroderma Treatment Market, By Drug Class
- Systemic Scleroderma Treatment Market, By Type
- Systemic Scleroderma Treatment Market, By Route of Administration
- Systemic Scleroderma Treatment Market, By Distribution Channel
- Systemic Scleroderma Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Epidemiology

4. Systemic Scleroderma Treatment Market, By Drug Class, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Immunosuppressant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phosphodiesterase 5 inhibitors - PHA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Endothelin Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Prostacyclin Analogues
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Systemic Scleroderma Treatment Market, By Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Limited Systemic Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Diffused Systemic Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Sine Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Systemic Scleroderma Treatment Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Systemic Scleroderma Treatment Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Systemic Scleroderma Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Certa Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Aisa Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Corbus Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgen Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
ONO PHARMACEUTICAL CO., LTD.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
MediciNova, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

硬皮症药物市场：依药物类别、类型、给药途径、分销管道、地区

Systemic Scleroderma Treatment Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography

市场动态：

本报告的主要特点

目录

第一章分析目的与前提

第二章市场展望

第三章市场动态、法规与趋势分析

第四章系统性硬皮症药物市场：依药物类别，2019-2031（十亿美元）

第五章系统性硬皮症治疗市场：依类型分类，2019-2031（十亿美元）

第六章系统性硬皮症药物市场：依给药途径划分，2019-2031 年（十亿美元）

第七章系统性硬皮症治疗市场：依通路划分，2019-2031（十亿美元）

第八章全球系统性硬皮症药物市场：按地区划分，2019-2031 年（十亿美元）

第9章竞争格局

第10章分析师建议

第十一章参考文献与调查方法

Market Dynamics:

Key Features of the Study:

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Systemic Scleroderma Treatment Market, By Drug Class, 2019-2031, (USD Bn)

5. Systemic Scleroderma Treatment Market, By Type, 2019-2031, (USD Bn)

6. Systemic Scleroderma Treatment Market, By Route of Administration, 2019-2031, (USD Bn)

7. Systemic Scleroderma Treatment Market, By Distribution Channel, 2019-2031, (USD Bn)

8. Global Systemic Scleroderma Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

硬皮症药物市场：依药物类别、类型、给药途径、分销管道、地区

Systemic Scleroderma Treatment Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography

市场动态：

本报告的主要特点

目录

第一章 分析目的与前提

第二章 市场展望

第三章市场动态、法规与趋势分析

第四章系统性硬皮症药物市场：依药物类别，2019-2031（十亿美元）

第五章系统性硬皮症治疗市场：依类型分类，2019-2031（十亿美元）

第六章 系统性硬皮症药物市场：依给药途径划分，2019-2031 年（十亿美元）

第七章系统性硬皮症治疗市场：依通路划分，2019-2031（十亿美元）

第八章全球系统性硬皮症药物市场：按地区划分，2019-2031 年（十亿美元）

第9章 竞争格局

第10章分析师建议

第十一章 参考文献与调查方法

Market Dynamics:

Key Features of the Study:

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Systemic Scleroderma Treatment Market, By Drug Class, 2019-2031, (USD Bn)

5. Systemic Scleroderma Treatment Market, By Type, 2019-2031, (USD Bn)

6. Systemic Scleroderma Treatment Market, By Route of Administration, 2019-2031, (USD Bn)

7. Systemic Scleroderma Treatment Market, By Distribution Channel, 2019-2031, (USD Bn)

8. Global Systemic Scleroderma Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

第一章分析目的与前提

第二章市场展望

第六章系统性硬皮症药物市场：依给药途径划分，2019-2031 年（十亿美元）

第9章竞争格局

第十一章参考文献与调查方法